Microbiological efficacy of 3-day treatment with azithromycin 1.5% eyedrops for purulent bacterial conjunctivitis

European Journal of Ophthalmology

Volumn 18, Issue 6, 2008, Pages 858-868

  Denis, François ^a   Chaumeil, C ^a   Goldschmidt, P ^a   Delval, L ^a   Pouliquen, P ^a   Cochereau, I ^a   Chainier, D ^a   De Barbeyrac, B ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Bacterial microbiology; Clinical activity spectrum; Purulent bacterial conjunctivitis; Resistance; Short course treatment; Topical azithromycin

Indexed keywords

AZITHROMYCIN; AZYTER; T 1225; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; EYE DROPS;

ACINETOBACTER; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTERIACEAE; ERADICATION THERAPY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; BACTERIUM; COMPARATIVE STUDY; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; TIME; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIA; CHILD; CHILD, PRESCHOOL; CONJUNCTIVA; CONJUNCTIVITIS, BACTERIAL; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OPHTHALMIC SOLUTIONS; TIME FACTORS; TOBRAMYCIN; YOUNG ADULT;

EID: 58149376740     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800602     Document Type: Article

References (54)

1. Syed NA, Chandler JW. Bacterial conjunctivitis. In: Tabbara KF, Hyndiuk RA, eds. Infections of the Eye. Boston, MA: Little, Brown and Co, 1996; 27: 423-31.
2. Hwang DG. Bacterial conjunctivitis. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection & Immunity. Saint Louis, MO: Mosby, 1996; 62: 799-817.
3. Sheikh A, Hurwitz B, Cave J. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2000; 2: CD001211.
4. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract 2001; 51: 473-7.
5. Everitt HA, Little PS, Smith PW. A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice [erratum in 2006; 333: 468]. BMJ 2006; 333: 321-6.
6. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update. Br J Gen Pract 2005; 55: 962-4.
7. Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2006; CD001211.
8. Sheikh A. Acute bacterial conjunctivitis. In: Wormald R, Smeeth L, Henshaw K, eds. Evidence-Based Ophthalmology. London, UK: BMJ Books, 2004; 5: 33-5.
9. Drew RH, Gallis HA. Azithromycin - spectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy 1992; 12: 161-73.
10. Fechner PU, Teichmann KD. The conjunctiva. In: Fechner PU, Teichmann KD, eds. Ocular Therapeutics Pharmacology and Clinical Application. Thorofare, NJ: Slack Inc., 1998; 15: 285-326.
11. Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician 1998; 57: 735-46.
12. Soukiasian SH, Baum J. Bacterial conjunctivitis. 2nd Edition. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. Philadelphia, PA: Elsevier Mosby, 2005; 49: 615-28.
13. Magnier B, Magnier M, Liotet S, Warnet JM, Henry JG, Huet JF. L'antibiotherapie en ophtalmologie. J Fr Ophtalmol 1984; 7: 499-506.
14. Stroman DW, Cupp GA, Schlech BA. Microbiology of bacterial conjunctivitis (1999-2003). ARVO. Fort Lauderdale, FL; May 1-5, 2005. 2005; 5066/B269.
15. Gigliotti F, Williams WT, Hayden FG, et al. Etiology of acute conjunctivitis in children. J Pediatr 1981; 98: 531-6.
16. Gross RD, Hoffman RO, Lindsay RN. A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. Clin Pediatr (Phila) 1997; 36: 435-44.
17. Cochereau I, Goldschmidt P, Goepogui A, et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial. Br J Ophthalmol 2006; 91: 667-72.
18. Ben Ali F, Golstein FW, Acar JF. In vitro activity of macrolides against traditional susceptible bacteria. In: Schönfeld W, Kirst HA, eds. Macrolide Antibiotics. Basel, Switzerland: Birkhaüser Verlag, 2002; 185-200.
19. Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 2004; 10: 3045-53.
20. Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44: 750-99.
21. Soriano F, Ponte C. Rational basis for optimizing antibiotic dosing regimens. Folia Med (Plovdiv) 2004; 46: 5-8.
22. Treadway G. Azithromycin: a new 15-membered macrolide. Jpn J Antibiot 2001; 54 (Suppl A): S70-6.
23. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001; 61: 443-98.
24. Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 2004; 18: 621-49.
25. Tabbara KF, al Kharashi SA, al Mansouri SM, et al. Ocular levels of azithromycin. Arch Ophthalmol 1998; 116: 1625-8.
26. Cochereau I, Meddeb-Ouertani A, Khairallah M, et al. 3-day treatment with azithromycin 1.5% eyedrops (Azyter(R)) versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol 2007; 91: 465-9.
27. Bloom PA, Leeming JP, Power W, Laidlaw DA, Collum LM, Easty DL. Topical ciprofloxacin in the treatment of blepharitis and blepharoconjunctivitis. Eur J Ophthalmol 1994; 4: 6-12.
28. Cagle G, Davis S, Rosenthal A, Smith J. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res 1981; 1: 523-34.
29. Cagle GD, Abshire RL. Quantitative ocular bacteriology: a method for the enumeration and identification of bacteria from the skin-lash margin and conjunctiva. Invest Ophthalmol Vis Sci 1981; 20: 751-7.
30. Gwon A. Ofloxacin vs tobramycin for the treatment of external ocular infection. Ofloxacin Study Group II. Arch Ophthalmol 1992; 110: 1234-7.
31. Jacobson JA, Call NB, Kasworm EM, Dirks MS, Turner RB. Safety and efficacy of topical norfloxacin versus tobramycin in the treatment of external ocular infections. Antimicrob Agents Chemother 1988; 32: 1820-4.
32. Jauch A, Fsadni M, Gamba G. Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis. Graefes Arch Clin Exp Ophthalmol 1999; 237: 705-13.
33. Milazzo G, Papa V, Carstocea B, et al. Topical netilmicin compared with tobramycin in the treatment of external ocular infection. Int J Clin Pharmacol Ther 1999; 37: 243-8.
34. Wilhelmus KR, Liesegang TJ, Osato MS, Jones DB, Specter SC. Laboratory diagnosis of ocular infections. Cumitech 13A. Washington, DC: ASM Press, American Society for Microbiology, 1984: 1-39.
35. Hwang DG, Schanzlin DJ, Rotberg MH, Foulks G, Raizman MB. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol 2003; 87: 1004-9.
36. Lichtenstein SJ, Rinehart M. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS 2003; 7: 317-24.
37. Rietveld RP, ter Riet G, Bindels PJ, Sloos JH, van Weert HC. Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. BMJ 2004; 329: 206-10.
38. Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 2003; 110: 457-65.
39. Gallenga PE, Lobefalo L, Colangelo L et al. Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: a multicenter double-blind phase III study. Ophthalmologica 1999; 213: 250-7.
40. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 1991; 112 (Suppl): S29-33.
41. Yee RW, Tepedino M, Bernstein P, Jensen H, Schiffman R, Whitcup SM. A randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis. Curr Med Res Opin 2005; 21: 425-31.
42. Jackson WB, Low DE, Dattani D, Whitsitt PF, Leeder RG, MacDougall R. Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Can J Ophthalmol 2002; 37: 228-37.
43. Tabbara KF, El Sheikh HF, Islam SM, Hammouda E. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%. Eur J Ophthalmol 1999; 9: 269-75.
44. File TM Jr., Schlemmer B, Garau J, Cupo M, Young C. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 2001; 48: 67-74.
45. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746-54.
46. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501-13.
47. Scortti M, Lacharme-Lora L, Wagner M, Chico-Calero I, Losito P, Vazquez-Boland JA. Coexpression of virulence and fosfomycin susceptibility in Listeria: molecular basis of an antimicrobial in vitro-in vivo paradox. Nat Med 2006; 12: 515-7.
48. Hunt GS, Citron DM, Claros MC, Goldstein EJ. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. Antimicrob Agents Chemother 1996; 40: 2413-5.
49. Philippon A, Cluzel R, Soussy CJ. Azithromycine: points critiques. Pathol Biol (Paris) 1995; 43: 488-97.
50. Lascols C, Bryskier A, Soussy CJ, Tankovic J. Effect of pH on the susceptibility of Helicobacter pylori to the ketolide telithromycin (HMR 3647) and clarithromycin. J Antimicrob Chemother 2001; 48: 738-40.
51. Baum J. Antibiotic mechanisms. 2nd Edition. In: Smolin G, Thoft RA, eds. The Cornea: Scientific Foundations and Clinical Practice. 2nd Edition. Boston, MA: Little, Brown and Co., 1987; 4: 179-89.
52. Brinser JH, Burd EM. Principles of diagnostic ocular microbiology. 2nd Edition. In: Tabbara KF, Hyndiuk RA, eds. Infections of the Eye. Boston, MA: Little, Brown and Co., 1986; 8: 69-84.
53. Kernt K, Martinez MA, Bertin D, et al. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis. Eur J Ophthalmol 2005; 15: 541-9.
54. Yolton DP. Antiinfective drugs. 4th edition. In: Bartlett JD, Jaanus SD, Blaho KE, Fiscella RG, Holdeman NR, Terry JE, eds. Clinical Ocular Pharmacology. Boston, MA: Butter-worth, Heinemann, 2001; 11: 219-64.